Atherosclerotic cardiovascular disease is projected to affect 38.7 percent of the United States population, roughly 125.7 million people, by 2060, and a new narrative review published in Cardiology and Therapy argues that the way clinicians manage lipids to prevent it is undergoing a fundamental transformation. The review, authored by Andrew Carlson, Zaid A. Zayyad, Adhir R. Shroff and colleagues, synthesizes literature published through April 2026, including practice guidelines, landmark randomized trials and major observational studies, and describes a shift away from a model centered solely on low-density lipoprotein cholesterol toward a more comprehensive assessment that incorporates apolipoprotein B, triglycerides and lipoprotein(a).
The mechanistic foundation for this shift rests on the cumulative nature of atherosclerosis. The duration of exposure to LDL cholesterol is associated with cardiovascular risk, and individuals with greater LDL exposure earlier in life face higher coronary artery disease risk even when their levels in midlife are similar. Across multiple trials using different therapies, coronary risk reduction has proven proportional to the absolute amount of LDL cholesterol lowered. In a 2016 meta-regression analysis, each 38.7 mg/dl reduction in LDL was associated with a relative cardiovascular risk of 0.77 with statins and 0.75 with established non-statin interventions. A Danish study stratifying patients above and below age 70 found that the same LDL reduction was associated with a 23 percent reduction in hospitalizations for acute coronary syndrome, non-hemorrhagic stroke and coronary revascularization regardless of age group.
The most consequential change described in the review is the updated 2026 American College of Cardiology/American Heart Association dyslipidemia guideline, which abandons the prior pooled cohort equations in favor of the PREVENT-ASCVD risk prediction model. This model estimates both 10-year and 30-year risk for total cardiovascular disease, beginning at age 30, and is personalized through risk-enhancing factors such as metabolic syndrome, chronic kidney disease and lipoprotein(a). The guideline introduces a new recommendation to measure Lp(a) once in a lifetime in all individuals, endorses apolipoprotein B measurement in select situations for discerning residual risk, and incorporates coronary artery calcium scoring as a key tool for statin decisions in borderline and intermediate-risk cases. By contrast, the European Society of Cardiology/European Atherosclerosis Society guidelines rely on predefined risk categories from the SCORE2 and SCORE2-OP charts to set LDL targets, using Lp(a) and calcium scoring mainly to reclassify patients among those categories.
The rationale for lifetime risk estimation is grounded in evidence that traditional short-term calculators systematically misclassify danger. More than half of adults with low estimated 10-year risk of ASCVD or heart failure actually carry high long-term risk, because conventional equations do not capture cumulative exposure to causal risk factors, genetic predisposition, environmental exposures or social determinants of health. Older calculators also perform poorly in young adults, even though dyslipidemia affects many people before the traditional 40-to-70 age window. Heterozygous familial hypercholesterolemia, which affects 1 in 250 to 300 people, often goes undetected because many individuals with markedly elevated LDL do not report a family history of hypercholesterolemia or early cardiovascular events. The new ACC/AHA guidance recommends screening beginning in young adulthood, with reassessment roughly every 5 years for those at average risk, and lipid screening starting at age 19.
On the treatment side, the 2026 ACC/AHA guideline has evolved from threshold-based frameworks to a hybrid strategy combining explicit LDL cholesterol goals, percentage reduction targets and individualized risk assessment. For a middle-aged patient with risk-enhancing factors, an LDL of 140 mg/dl on a moderate-intensity statin and a calculated 10-year PREVENT risk of 18 percent, prior guidance would have focused mainly on escalating to a high-intensity statin without a specific goal; the new guideline favors explicit LDL reduction targets and earlier combination therapy to reach them. Non-statin escalation proceeds stepwise, adding ezetimibe, PCSK9 inhibitors, bempedoic acid or inclisiran when goals are not met, with cost, access and patient preference explicitly built in. The European and American Association of Clinical Endocrinology guidelines instead advocate earlier and more intensive combination therapy tied to predefined thresholds, with AACE more clearly endorsing bempedoic acid and taking a cautious position on inclisiran.
The evidence supporting earlier combination therapy has accumulated steadily. The RACING trial showed that moderate-intensity statin plus ezetimibe was noninferior to high-intensity statin monotherapy for major cardiovascular outcomes, with better LDL goal attainment and fewer intolerance-related discontinuations, while IMPROVE-IT had previously established incremental benefit from adding ezetimibe to statin therapy in high-risk patients. Meanwhile, the safety of very low LDL levels has been reinforced: in FOURIER, evolocumab lowered median LDL to approximately 30 mg/dl and reduced major cardiovascular events, and long-term extension data down to levels below 20 mg/dl showed no adverse neurological, hormonal or cardiometabolic effects. ODYSSEY OUTCOMES showed cardiovascular benefit with alirocumab in post-ACS patients achieving very low LDL, and the EBBINGHAUS substudy found no significant cognitive decline with intensive lowering. These data underpin European targets below 55 mg/dl for very high-risk patients.
Coronary artery calcium scoring occupies an increasingly prominent but carefully bounded role. It is strongly associated with 10-year ASCVD risk as an independent factor and is most appropriate for asymptomatic men aged 40 or older and women aged 45 or older at borderline risk when the decision to start a statin is uncertain. A score of zero can be used to defer therapy and a score of 100 or above favors initiation, though calcification develops late in atherosclerosis, making the test less useful in young patients where a zero score can be falsely reassuring despite meaningful lifetime risk. The review notes that no randomized trial has yet proven that calcium screening reduces myocardial infarction or mortality; its value lies in risk prediction and medication management rather than demonstrated outcome benefit.
Beyond LDL, the review highlights residual risk pathways. Lipoprotein(a) is a genetically determined, largely lifestyle-independent causal risk factor with pro-atherogenic and pro-thrombotic properties; a level of 50 mg/dl, present in about 20 percent of the population, carries roughly 40 percent higher relative risk than the population median. Statins and lifestyle change have negligible effect on it, PCSK9 inhibitors produce modest reductions, and the only FDA-approved treatment for high-risk patients with familial hypercholesterolemia and elevated Lp(a) not meeting lipid goals remains lipoprotein apheresis. Antisense and siRNA therapies have cut circulating Lp(a) by up to 80 percent with pelacarsen and more than 90 percent with olpasiran in dose-dependent fashion, but those studies were not designed to assess cardiovascular outcomes, so whether selective lowering translates into fewer events remains unknown. Inflammation is another modifier: in the REPRIEVE trial, pitavastatin reduced major adverse cardiovascular events by 35 percent versus placebo in people with HIV, and JUPITER showed that moderate-intensity rosuvastatin significantly reduced major events in patients with normal LDL but elevated high-sensitivity C-reactive protein.
For triglycerides, elevated levels are well established as associated with increased ASCVD risk and all-cause mortality, and a study in heart failure patients described a U-shaped association in which high triglycerides of 265.8 mg/dl or above were linked to ASCVD admission or death while very low levels below 106.3 mg/dl were linked to higher heart failure readmission or mortality, possibly reflecting frailty or malnutrition. Traditional triglyceride-lowering drugs have shown variable and often inconsistent cardiovascular effects, with icosapent ethyl the notable exception in high-risk patients on statins. Novel agents targeting apolipoprotein C-III are advancing: plozasiran significantly reduced ApoC-III and triglycerides in severe hypertriglyceridemia in the SHASTA-2 trial, and the antisense oligonucleotide olezarsen reduced triglycerides and acute pancreatitis incidence versus placebo.
The review closes with future directions that remain investigational. Inclisiran, a small interfering RNA targeting hepatic PCSK9 synthesis, produces sustained LDL reductions of approximately 50 percent with twice-yearly dosing, but definitive cardiovascular outcomes data are pending in the ongoing ORION-4 and VICTORION-2P trials. Polygenic risk scores, which aggregate hundreds of thousands of common variants, identified 8 percent of the UK Biobank population as carrying a threefold increased coronary artery disease risk comparable to monogenic familial hypercholesterolemia, including people who would not be flagged by LDL, hypertension or family history alone. A significant limitation is reduced predictive accuracy in non-European populations, and the authors caution that broader validation and equitable implementation are needed before widespread adoption. As a narrative review, the synthesis was not conducted through a formal systematic process and may be subject to selection bias, and the authors note that lipid guidelines continue to evolve rapidly as new evidence emerges.
Subject of Research: Modern lipid management and evolving guidelines for atherosclerotic cardiovascular disease prevention in primary care
Article Title: Beyond LDL-C: Modern Lipid Management for ASCVD Prevention in Primary Care
Article References: Carlson, A., Zayyad, Z. A., Driesenga, S., Boxley, P., Mishra, A., Uraizee, O., Ephrem, R., Zhang, R., Natsheh, Z., & Shroff, A. R. (2026). Beyond LDL-C: Modern Lipid Management for ASCVD Prevention in Primary Care. Cardiology and Therapy, 15(3), 481-501. https://doi.org/10.1007/s40119-026-00473-5
Image Credits: AI Generated
DOI: 10.1007/s40119-026-00473-5
Keywords: LDL cholesterol, ASCVD prevention, lipoprotein(a), PREVENT risk model, coronary artery calcium, statin therapy, PCSK9 inhibitors, ezetimibe, apolipoprotein B, triglycerides, polygenic risk scores, primary care
News Source: Ophelia Keating. (October 29, 2026). Cholesterol Care Moves Past LDL as Guidelines Embrace Lifetime Risk. Scienmag.
